GVK Bio says it is adding master cell banking services to get in the GMP mindset, with a longer-term goal to expand into clinical and commercial production.

Dan Stanton, Managing editor

January 9, 2020

2 Min Read
GVK Bio looks to ‘big-ticket’ manufacturing after building up bioservices biz
Image: iStock/MeePoohyaphoto

GVK Bio says it is adding master cell banking services to get in the GMP mindset, with a longer-term goal to expand into clinical and commercial production.

In 2014, Indian contract research organization (CRO) GVK Bio landed both in the US and in the biologics services space by acquiring Aragen Bioscience. Aragen comprises of two sites in San Francisco offering efficacy studies, protein analytics, and cell line development services.

At the time, “Aragen’s scientific excellence and expertise in large-molecule R&D services” were cited as drivers in the deal, and five years on GVK Bio now hopes to use the acquisition as a springboard into GMP manufacturing.


Image: iStock/MeePoohyaphoto

GVK Bio has invested into Aragen since the acquisition, doubling its biologics laboratory space to support demand for cell line development services. The firm uses the royalty-free DG44 cell line, which it says it has optimized to effectively double the titer, and while it is attracting substantial business in this space, Ramesh Subramanian, chief commercial officer of GVK Bio said it is missing out on the “big-ticket item” of GMP manufacturing.

“After developing a successful cell line, customers want to move into manufacturing and want us to carry out a tech transfer,” he told Bioprocess Insider at the CPhI Worldwide event in Frankfurt last November. “With cell line development services and no manufacturing capacity, we are losing out on the big-ticket item.”

As such, plans are afoot to broaden out services and add biomanufacturing to GVK/Aragen’s arsenal. The first stage, Subramanian said, is to add master cell banking (MCB) services “to get in the GMP thinking.”

A facility has already been built and is set to be operational in January as “an interim phase,” and an investment decision for manufacturing capabilities will be made by September 2020, we were told.

Specific decisions have not yet been made, but Subramanian said the initial investment will be to support Phase I-II clinical trials and comprised of completely disposable components, offering “speed and flexibility – what people want.”

He also estimated that if this project is done organically it will require around $10 million in investment, though an inorganic move into GMP manufacturing is also an option.

“In small molecules, we already offer end-to-end services, and in biologics our eventual goal is to offer gene-to-clinic development.”

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.

Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like